ACP-105 / 100 x 5mg

Description

ACP-105 is a synthetic non-steroidal Selective Androgen Receptor Modulator (SARM) developed as a potential treatment for muscle wasting, osteoporosis, and age-related anabolic decline. It is notable for its high binding affinity to androgen receptors and rapid onset of action, while maintaining a favorable tissue selectivity profile.

In vivo data from animal models indicate that ACP-105 exhibits a high anabolic-to-androgenic activity ratio, promoting increases in skeletal muscle mass and bone mineral density while eliciting minimal activation in androgen-sensitive peripheral tissues such as the prostate. These effects have been achieved without significant androgenic liabilities typically observed with classical steroidal agents. Additionally, the compound’s pharmacokinetics suggest a relatively rapid onset of action and a short systemic half-life, which may support temporal precision in experimental settings.

In research environments, ACP-105 has been associated with:

• Anabolic activity in skeletal muscle tissue, with increases in muscle mass and functional output observed in animal models of cachexia and age-associated sarcopenia.
• Osteoanabolic effects, including improved bone mineral density and biomechanical strength, as observed in rodent models of bone degeneration.
• Tissue-selective androgen receptor modulation, with limited activity in androgen-sensitive peripheral tissues such as the prostate and sebaceous glands, suggesting a reduced propensity for androgenic off-target effects in non-musculoskeletal systems.
• Neuromotor and behavioral modulation, including enhanced motor coordination and cognitive performance in irradiated and neurodegenerative rodent models, potentially mediated through central nervous system androgen receptor engagement.

••Pharmacokinetic profile characterized by a relatively short elimination half-life (estimated 4–6 hours), enabling temporally precise modulation in experimental paradigms requiring rapid onset and offset of action.

Although human data is limited, ACP-105 is considered a promising research candidate for anabolic and neuromuscular applications, with particular interest in its safety margin and pharmacokinetics.

CAS Number: 899821-23-9
Molecular formula: C16H19ClN2O
Purity: ≥99% (see HPLC and COA documentation)
Concentration: 5 mg
Molar mass: 290.79 g/mol
Half-life: Estimated ~4–6 hours

⚠ Important Note: This product is supplied strictly for laboratory research use only. It is not approved for human consumption or therapeutic use. Not intended to diagnose, treat, cure, or prevent any disease.